TNF Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Loss Per Share (Details Narrative)

Loss Per Share (Details Narrative) (USD $)	12 Months Ended
Loss Per Share (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Net loss attributable to common stockholders	$ (3,142,960)	$ (1,526,773)
Basic and diluted weighted average number of common shares outstanding	4,745,684	1,596,722
Incentive and Award Stock Options [Member]
Anti-dilutive securities excluded from earning per shares	175,000
Warrant [Member]
Anti-dilutive securities excluded from earning per shares	1,989	1,989

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References + Details